Dowling & Yahnke’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $7.99M | Sell |
112,413
-2,023
| -2% | -$147K | 0.37% | 66 |
|
|
2022
Q2 | $8.81M | Buy |
114,436
+4,701
| +4% | +$358K | 0.41% | 57 |
|
|
2022
Q1 | $8.01M | Buy |
109,735
+2,432
| +2% | +$163K | 0.35% | 80 |
|
|
2021
Q4 | $6.69M | Sell |
107,303
-4,718
| -4% | -$277K | 0.32% | 92 |
|
|
2021
Q3 | $6.63M | Sell |
112,021
-1,199
| -1% | -$79K | 0.37% | 86 |
|
|
2021
Q2 | $7.57M | Buy |
113,220
+702
| +0.6% | +$45.8K | 0.43% | 72 |
|
|
2021
Q1 | $7.1M | Buy |
112,518
+714
| +0.6% | +$44.4K | 0.49% | 64 |
|
|
2020
Q4 | $6.93M | Buy |
111,804
+1,750
| +2% | +$108K | 0.49% | 61 |
|
|
2020
Q3 | $6.63M | Sell |
110,054
-2,324
| -2% | -$140K | 0.53% | 60 |
|
|
2020
Q2 | $6.61M | Buy |
112,378
+3,348
| +3% | +$200K | 0.55% | 54 |
|
|
2020
Q1 | $6.08M | Sell |
109,030
-5,560
| -5% | -$340K | 0.59% | 53 |
|
|
2019
Q4 | $7.36M | Buy |
114,590
+27,920
| +32% | +$1.6M | 0.56% | 57 |
|
|
2019
Q3 | $4.39M | Sell |
86,670
-1,312
| -1% | -$61.7K | 0.36% | 81 |
|
|
2019
Q2 | $3.99M | Sell |
87,982
-5,644
| -6% | -$263K | 0.33% | 87 |
|
|
2019
Q1 | $4.47M | Buy |
93,626
+3,685
| +4% | +$184K | 0.43% | 70 |
|
|
2018
Q4 | $4.81M | Sell |
89,941
-2,089
| -2% | -$112K | 0.5% | 66 |
|
|
2018
Q3 | $5.71M | Sell |
92,030
-756
| -0.8% | -$44.9K | 0.5% | 69 |
|
|
2018
Q2 | $5.13M | Sell |
92,786
-4,916
| -5% | -$266K | 0.48% | 67 |
|
|
2018
Q1 | $6.18M | Sell |
97,702
-1,581
| -2% | -$102K | 0.58% | 57 |
|
|
2017
Q4 | $6.08M | Sell |
99,283
-3,048
| -3% | -$191K | 0.55% | 62 |
|
|
2017
Q3 | $6.52M | Buy |
102,331
+3,209
| +3% | +$187K | 0.66% | 49 |
|
|
2017
Q2 | $5.52M | Buy |
99,122
+416
| +0.4% | +$22.6K | 0.58% | 58 |
|
|
2017
Q1 | $5.37M | Sell |
98,706
-412
| -0.4% | -$22.6K | 0.57% | 61 |
|
|
2016
Q4 | $5.79M | Sell |
99,118
-1,808
| -2% | -$98.8K | 0.65% | 49 |
|
|
2016
Q3 | $5.44M | Buy |
100,926
+2,140
| +2% | +$137K | 0.64% | 51 |
|
|
2016
Q2 | $7.27M | Sell |
98,786
-6
| -0% | -$424 | 0.87% | 26 |
|
|
2016
Q1 | $6.31M | Buy |
98,792
+720
| +0.7% | +$45.4K | 0.78% | 34 |
|
|
2015
Q4 | $6.75M | Sell |
98,072
-1,508
| -2% | -$99.7K | 0.85% | 24 |
|
|
2015
Q3 | $5.89M | Buy |
99,580
+886
| +0.9% | +$56.2K | 0.8% | 32 |
|
|
2015
Q2 | $6.57M | Sell |
98,694
-710
| -0.7% | -$46.8K | 0.83% | 29 |
|
|
2015
Q1 | $6.41M | Buy |
99,404
+16
| +0% | +$1K | 0.8% | 27 |
|
|
2014
Q4 | $5.87M | Sell |
99,388
-1,391
| -1% | -$78.4K | 0.73% | 38 |
|
|
2014
Q3 | $5.16M | Sell |
100,779
-5,039
| -5% | -$252K | 0.68% | 43 |
|
|
2014
Q2 | $5.13M | Sell |
105,818
-57
| -0.1% | -$2.81K | 0.66% | 45 |
|
|
2014
Q1 | $5.5M | Buy |
105,875
+8,739
| +9% | +$465K | 0.72% | 36 |
|
|
2013
Q4 | $5.16M | Buy |
97,136
+1,116
| +1% | +$56.8K | 0.73% | 40 |
|
|
2013
Q3 | $4.44M | Sell |
96,020
-1,430
| -1% | -$62.8K | 0.7% | 41 |
|
|
2013
Q2 | $4.36M | Buy |
+97,450
| New | +$4.23M | 0.73% | 40 |
|
Other funds holding BMY
Dowling & Yahnke's BMY Position: Q3 2022 in Review
Dowling & Yahnke reduced its Bristol-Myers Squibb (BMY) stake by 1.8% in Q3 2022, selling an estimated $147K and leaving 112,413 shares worth $7.99M. The position accounts for 0.37% of the portfolio, ranked #66.
Dowling & Yahnke first reported a position in BMY in Q2 2013 and has held it in 38 quarters since. The position peaked at $8.81M in Q2 2022. 2,470 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- Dowling & Yahnke held 112,413 shares of Bristol-Myers Squibb worth $7.99M as of Q3 2022.
- Dowling & Yahnke sold 2,023 Bristol-Myers Squibb shares in Q3 2022, an estimated $147K.
- Bristol-Myers Squibb made up 0.37% of Dowling & Yahnke's portfolio in Q3 2022, its #66 holding.
- Dowling & Yahnke first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Bristol-Myers Squibb position peaked at $8.81M in Q2 2022.
- 2,470 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.